Peter L. Jones

4.7k total citations
64 papers, 3.6k citations indexed

About

Peter L. Jones is a scholar working on Molecular Biology, Genetics and Genetics. According to data from OpenAlex, Peter L. Jones has authored 64 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Molecular Biology, 15 papers in Genetics and 9 papers in Genetics. Recurrent topics in Peter L. Jones's work include Muscle Physiology and Disorders (33 papers), Neurogenetic and Muscular Disorders Research (9 papers) and RNA modifications and cancer (9 papers). Peter L. Jones is often cited by papers focused on Muscle Physiology and Disorders (33 papers), Neurogenetic and Muscular Disorders Research (9 papers) and RNA modifications and cancer (9 papers). Peter L. Jones collaborates with scholars based in United States, Australia and Netherlands. Peter L. Jones's co-authors include Paul A. Wade, Takako I. Jones, Alan P. Wolffe, Jeremy M. Boss, Dongsheng Ping, Charis L. Himeda, Danielle Vermaak, Yun‐Bo Shi, Ryan D. Wuebbles and Bruce D. Sidell and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Peter L. Jones

63 papers receiving 3.5k citations

Peers

Countries citing papers authored by Peter L. Jones

Since Specialization

Citations

This map shows the geographic impact of Peter L. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter L. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter L. Jones more than expected).

Fields of papers citing papers by Peter L. Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter L. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter L. Jones. The network helps show where Peter L. Jones may publish in the future.

Co-authorship network of co-authors of Peter L. Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Peter L. Jones. A scholar is included among the top collaborators of Peter L. Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter L. Jones. Peter L. Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	All-in-one vectors for epigenetic CRISPR inhibition of DUX4-fl in facioscapulohumeral muscular dystrophy 2025 ·Molecular Therapy — Methods & Clinical Development ·Charis L. Himeda, Takako I. Jones, Peter L. Jones	0
2	Have a Little Heart (or Not): Highly Minimized Skeletal Muscle Regulatory Cassettes with Low or No Activity in the Heart 2024 ·Human Gene Therapy ·Charis L. Himeda, Takako I. Jones, Peter L. Jones	2
3	Regional and bilateral MRI and gene signatures in facioscapulohumeral dystrophy: implications for clinical trial design and mechanisms of disease progression 2024 ·Human Molecular Genetics ·Chao-Jen Wong, Seth D. Friedman, Lauren Snider, Sean Bennett, Takako I. Jones, Peter L. Jones, Dennis Shaw, Silvia S. Blemker, (unknown), (unknown), Richard J.L.F. Lemmers, Silvère M. van der Maarel, Leo H. Wang, Rabi Tawil, Jeffrey Statland, Stephen J. Tapscott	10
4	Muscle eosinophilia is a hallmark of chronic disease in facioscapulohumeral muscular dystrophy 2024 ·Human Molecular Genetics ·Andreia M. Nunes, (unknown), (unknown), Takako I. Jones, Peter L. Jones	1
5	Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy 2020 ·Proceedings of the National Academy of Sciences ·Kenji Rowel Q. Lim, Rika Maruyama, Yusuke Echigoya, Quynh Nguyen, Aiping Zhang, (unknown), (unknown), Takako I. Jones, Peter L. Jones, Yi-Wen Chen, Toshifumi Yokota	43
6	Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy 2020 ·Science Translational Medicine ·Angela Lek, Tracy Zhang, Keryn G. Woodman, Shushu Huang, Alec M. DeSimone, Justin Cohen, Vincent Ho, (unknown), (unknown), Andrew Kodani, (unknown), Neville E. Sanjana, Oliver D. King, Peter L. Jones, Kathryn R. Wagner, Monkol Lek, Louis M. Kunkel	45
7	Targeted epigenetic repression by CRISPR/dSaCas9 suppresses pathogenic DUX4-fl expression in FSHD 2020 ·Molecular Therapy — Methods & Clinical Development ·Charis L. Himeda, Takako I. Jones, Peter L. Jones	41
8	Tristearin as a Model Cuticle for High-Throughput Screening of Agricultural Adjuvant Systems 2018 ·ACS Omega ·Graham R. Webster, (unknown), David M. Cahill, Peter L. Jones, (unknown), Adrian Hawley, Ben J. Boyd	3
9	Large family cohorts of lymphoblastoid cells provide a new cellular model for investigating facioscapulohumeral muscular dystrophy 2016 ·Neuromuscular Disorders ·Takako I. Jones, Charis L. Himeda, (unknown), Peter L. Jones	18
10	Facioscapulohumeral Muscular Dystrophy As a Model for Epigenetic Regulation and Disease 2014 ·Antioxidants and Redox Signaling ·Charis L. Himeda, Takako I. Jones, Peter L. Jones	28
11	Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis 2012 ·Human Molecular Genetics ·Takako I. Jones, Jennifer C. J. Chen, Fedik Rahimov, Sachiko Homma, (unknown), Mary Lou Beermann, Oliver D. King, Jeffrey B. Miller, Louis M. Kunkel, Charles P. Emerson, Kathryn R. Wagner, Peter L. Jones	139
12	Facioscapulohumeral Muscular Dystrophy Region Gene 1 Is a Dynamic RNA-Associated and Actin-Bundling Protein 2011 ·Journal of Molecular Biology ·(unknown), Silvana van Koningsbruggen, (unknown), Kirsten R. Straasheijm, Rinse Klooster, Takako I. Jones, Michel Bellini, Lyne Lévesque, William M. Brieher, Silvère M. van der Maarel, Peter L. Jones	22
13	Muscular dystrophy candidate gene FRG1 is critical for muscle development 2008 ·Developmental Dynamics ·(unknown), Ryan D. Wuebbles, Peter L. Jones	42
14	Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia 2008 ·The Journal of Experimental Medicine ·Assam El‐Osta, Daniella Brasacchio, Dachun Yao, Alessandro Pocai, Peter L. Jones, Robert G. Roeder, Mark E. Cooper, Michael Brownlee	36
15	Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing 2005 ·Nature Genetics ·K N Harikrishnan, Maggie Zi Ying Chow, Emma K. Baker, Sharmistha Pal, Sahar Bassal, Daniella Brasacchio, Li Wang, Jeffrey M. Craig, Peter L. Jones, Saı̈d Sif, Assam El‐Osta	238
16	Programming the Transcriptional State of Replicating Methylated DNA 2001 ·Journal of Biological Chemistry ·Walter Stünkel, Slimane Ait‐Si‐Ali, Peter L. Jones, Alan P. Wolffe	3
17	A multiple subunit Mi-2 histone deacetylase from Xenopus laevis cofractionates with an associated Snf2 superfamily ATPase 1998 ·Current Biology ·Paul A. Wade, Peter L. Jones, Danielle Vermaak, Alan P. Wolffe	356
18	Tumor Necrosis Factor Alpha and Interleukin-1β Regulate the Murine Manganese Superoxide Dismutase Gene Through a Complex Intronic Enhancer Involving C/EBP-β and NF-κB 1997 ·Molecular and Cellular Biology ·Peter L. Jones, Dongsheng Ping, Jeremy M. Boss	212
19	TNF Regulates the In Vivo Occupancy of Both Distal and Proximal Regulatory Regions of the MCP-1/JE Gene 1996 ·Immunity ·Dongsheng Ping, Peter L. Jones, Jeremy M. Boss	117
20	Modern treatment of haemophilia. 1995 ·PubMed ·Erik Berntorp, Victor Boulyjenkov, Doreen B. Brettler, Mammen Chandy, Peter L. Jones, (unknown), (unknown), Pier Mannuccio Mannucci, (unknown), K.A. Rickard	156

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact